Haemato AG represents values of innovation, integrity, and excellence in the pharmaceutical industry. This German-based company is dedicated to providing high-quality products and services to patients and healthcare professionals worldwide. Haemato AG's corporate philosophy focuses on sustainable growth, customer satisfaction, and a strong commitment to research and development. With a diverse portfolio encompassing specialty pharmaceuticals, generics, and consumer health products, Haemato AG strives to meet the evolving needs of the market. Through its emphasis on quality, trust, and continuous improvement, Haemato AG positions itself as a reliable and respected player in the healthcare sector.

Haemato AG is primarily present in Germany, Austria, and Switzerland.

Haemato AG, a renowned pharmaceutical company, has achieved several notable milestones. With its commitment to excellence and innovation, the company has made significant progress. Haemato AG successfully launched new drugs and expanded its product portfolio, catering to diverse medical needs. Additionally, the company has experienced substantial growth in sales and market presence, establishing itself as a leading player in the healthcare sector. Furthermore, Haemato AG has fostered strategic partnerships and collaborations, driving research and development efforts. These achievements emphasize Haemato AG's dedication to improving medical treatment and addressing critical health challenges.

Haemato AG, a renowned pharmaceutical company, has a rich history and background. Established in 1993, the company has consistently positioned itself as a leading player in the healthcare sector. Haemato AG specializes in the development, production, and distribution of high-quality pharmaceuticals and medical devices. With a focus on innovation and customer satisfaction, Haemato AG has successfully expanded its product portfolio to cover various therapeutic areas, including oncology, neurology, and cardiology. The company's commitment to delivering reliable and affordable healthcare solutions has earned it a strong reputation in the industry. Haemato AG's consistent growth and dedication to improving patients' lives make it a compelling choice for investors seeking exposure to the pharmaceutical sector.

The main competitors of Haemato AG in the market include other pharmaceutical companies such as Pfizer Inc., Johnson & Johnson, Novartis AG, and Roche Holding AG.

Haemato AG is primarily active in the healthcare industry.

The business model of Haemato AG revolves around the distribution and sale of pharmaceutical products. As a healthcare company, Haemato AG specializes in the marketing, sourcing, and distribution of both branded and generic drugs. This German-based company takes pride in its strong network of partnerships with pharmaceutical manufacturers and suppliers, ensuring a diverse product portfolio. Haemato AG's business model focuses on the wholesale trade of pharmaceuticals and is committed to providing reliable and cost-effective healthcare solutions. With a comprehensive range of products and a customer-oriented approach, Haemato AG aims to meet the ever-growing demand for high-quality medicines in the market.

Pomer Haemato cena/zisk je 7,24.

Koeficient Haemato P/S je 0,26.

AlleAktien kvalitatívne skóre pre Haemato je 4/10.

Tržby spoločnosti očakávaná Haemato sú 279,89 mil. EUR.

Zisk očakávaná Haemato je 10,18 mil. EUR.

Haemato AG is a company specialized in the pharmaceutical market, primarily active in Germany and Europe. Their business model is based on selling medications, as well as marketing generics and biosimilars. In this text, the different divisions and products of Haemato AG are described in more detail. The company has three main divisions: Business-to-Business (B2B), Business-to-Consumer (B2C), and Business-to-Institution (B2I). In the B2B sector, the company distributes pharmaceuticals and medical products to pharmacies, hospitals, wholesalers, and other institutions. They offer secure logistics, quality guarantee, and an extensive range of products. In the B2C sector, Haemato sells its products directly to end customers, mainly through an online shop and its own pharmacies. This includes cosmetic products, dietary supplements, and medical devices. In the B2I sector, Haemato AG works closely with health insurance companies and doctors to provide high-quality and cost-effective medications through discount contracts. Haemato's product range is very extensive, including both branded products and generics and biosimilars. The company offers a wide spectrum of therapeutics, from painkillers to antidiabetic drugs. They also provide a range of products for rare diseases. Thanks to their own production facilities, the company can offer both cost-effective generics and high-quality biosimilars. To meet patient needs, Haemato AG also has its own clinic and care management. It enables a seamless process chain from medical prescription to patient care. Haemato works closely with clinics, care facilities, and other institutions to ensure optimal patient care. Other important elements of Haemato's business model are product diversification and expansion into international markets. The company pays particular attention to legal and regulatory conditions to ensure successful expansion. Overall, Haemato AG offers a very comprehensive business model focused on high quality and efficiency. With their broad product range and clinic and care management, the company is able to provide optimal patient care to their customers. Through diversification and international market expansion, Haemato AG aims for further growth in the future.

Haemato vypláca dividendu vo výške 1,10 EUR rozdelenú do výplat počas roka.

Dividenda pre Haemato sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Haemato je DE000A289VV1.

WKN spoločnosti Haemato je A289VV.

Ticker spoločnosti Haemato je HAEK.HM.

V posledných 12 mesiacoch spoločnosť Haemato vyplatila dividendu vo výške 1,10 EUR . To zodpovedá dividendovému výnosu približne 7,80 %. Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Haemato vyplácať dividendu 1,12 EUR.

Súčasný výnos z dividend spoločnosti Haemato je 7,80 %.

Haemato vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch august, august, august, august.

Haemato platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 1,12 EUR. To zodpovedá dividendovému výnosu 7,83 %.

Haemato je priradený sektoru 'Zdravie'.

Aby ste obdržali poslednú dividendu vo výške 1,2 EUR od Haemato z dňa 21. 7. 2023, museli ste mať akciu v depozite pred ex-dňom 19. 7. 2023.

Posledná dividenda bola vyplatená 21. 7. 2023.

V roku 2023 boli od Haemato 1,1 EUR vyplatené ako dividendy.

Dividendy spoločnosti Haemato sú vyplácané v EUR.